The economic burden of gout on an employed population

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1381-1389

  Brook, Richard A ^a   Kleinman, Nathan L ^b   Patel, Pankaj A ^c   Melkonian, Arthur K ^d   Brizee, Truman J ^b   Smeeding, James E ^a,e   Joseph Ridge, Nancy ^c  

^a JeSTARx Group   (United States)

^b Human Capital Management Services   (United States)

^c TAP Pharmaceuticals   (United States)

^d Human Capital Management Services   (Armenia)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Burden of illness; Cost of illness; Economics; Employees; Gout; Observational; Treatment costs

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; SULFINPYRAZONE;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; ENDOCRINE SYSTEM; FEMALE; GOUT; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; OUTPATIENT DEPARTMENT; PRESCRIPTION; STUDENT T TEST; WORKMAN COMPENSATION;

COSTS AND COST ANALYSIS; EMPLOYMENT; FEMALE; GOUT; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PRESCRIPTIONS, DRUG; SICK LEAVE; UNITED STATES; WORKERS' COMPENSATION;

EID: 33746154237     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X112606     Document Type: Article

References (41)

1. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59:925-34
2. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991;266:3004-7
3. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40:37-42
4. Adams PF, Hendershot GE, Marano MA. Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999;200:1-203
5. Troen BR. The biology of aging. Mt Sinai J Med 2003;70: 3-22
6. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6
7. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81
8. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103
9. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the US, 1998-2000. JAMA 2003;290:199-206
10. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-8
11. Bedir A, Topbas M, Tanyeri F, et al. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 2003;44:527-36
12. Ferdinand KC. Recommendations for the management of special populations: racial and ethnic populations. Am J Hypertens 2005;16:50S-4S
13. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5
14. Caspi D, Lubart E, Habot B, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-8
15. Reginato AJ. Gout and other crystal arthropathies. In: Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison's principles of internal medicine. 15th edn. New York: McGraw-Hill, 2001. p. 1995
16. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-81
17. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the art. Drugs 2004;64:2399-416
18. Kim KY, Schumacher HR, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617
19. Centers for Disease Control and Prevention (CDC). Prevalence of leisure-time physical activity among persons with arthritis and other rheumatic conditions - United States, 1990-1991. MMWR: Morb Mortal Wkly Rep 1997;46:389-93
20. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72
21. Stave GM, Muchmore L, Gardner HH. Quantifiable impact of the contract for health and wellness: health care costs, disability, and workers' compensation. Health behaviors, health care costs, disability, and workers' compensation. J Occup Environ Med 2003;45:109-17
22. Muchmore L, Lynch WD, Gardner HH, et al. Prevalence of arthritis and associated joint disorders in an employed population and the associated healthcare, sick leave, and workers' compensation benefits cost and productivity loss of employers. J Occup Environ Med 2003;45:369-78
23. Elixhauser A, Steiner C, Palmer L. Clinical classifications software, 2004. U.S. Agency for Healthcare and Research. Available from http://www.ahrq.gov/data/hcup/css.htm#download [Last accessed November 2004].
24. Also available through HCUP Methods Series: Report #2004-02 Comorbidity software documentation. Available from http://www.hcup-us.ahrq.gov/reports/ methods.jsp [Last accessed November 2004]
25. Blough D, Madden C, Hornbrook M. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71
26. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427-41
27. Wilder MH. Prevalence of chronic skin and musculoskeletal conditions, United States - 1969. Vital and Health Statistics 10 1974;92
28. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7
29. Employment status of the civilian noninstitutional population by age, sex, and race. Available from ftp://ftp.bls.gov/pub/special. requests/lf/aa2004/aat3.txt [Last accessed 6 April 2006]
30. Median weekly earnings of full-time wage and salary workers by selected characteristics. Available from ftp://ftp.bls.gov/pub/special.requests/lf/ aa2004/aat37.txt [Last accessed 6 April 2006]
31. Gignac MA. Arthritis and employment: an examination of behavioral coping efforts to manage workplace activity limitations. Arthritis Rheum 2005;53:328-36
32. Pascual E, Jovani V. Synovial fluid analysis. Best Pract Res Clin Rheumatol 2005;19:371-86
33. Bieber JD, Terkeltaub RA. Gout on the brink of novel therapeutic options for an ancient disease. Art Rheum 2004;50:2400-14
34. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52
35. Novak S. A comparison of average annual medical services for comorbid conditions associated with metabolic syndrome found in employees with gout versus those without gout. J Manag Care Pharm 2006;12:173
36. US Census Bureau. Annual estimates of the population by selected age groups and sex for the United States: April 1, 2000 to July 1, 2004. Available from http://www.census.gov/popest/national/asrh/NC-EST2004-sa.html [Last accessed August 2005]
37. Kaiser State health facts. Org: 50 state comparisons - population distribution by insurance status 2003. Available from http://www. statehealthfacts.org [Last accessed August 2005]
38. US Census Bureau. United States civilian labor force. Available from http://webs.wichita.edu/cedbr/usclf.PDF#search='United%2 Ostates%20civilian%20labor%20 force [Last accessed July 2005]
39. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51
40. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9
41. Sarawate CA, Patel PA, Schumacher HR, at al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5